CorMedix (CRMD) vs Kura Oncology (KURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Kura Oncology (KURA) has outperformed CorMedix (CRMD) over the past year, losing 7.7% versus a loss of 28.7%. Over five years, CRMD leads with a +52.8% price change compared with -48.3% for KURA. Kura Oncology is the larger company by market cap ($807.8 million vs $565.9 million), about 1.4 times the size, while CorMedix is growing revenue faster (+617.0% vs +25.2%).
CorMedix converts more of its revenue into profit, with a net margin of 52.3% versus -412.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | KURA |
|---|---|---|
| Share price | $7.26 | $9.08 |
| Market cap | $565.88M | $807.76M |
| 1-day change | -2.68% | -6.39% |
| YTD return | -37.58% | -12.61% |
| 1-year return | -28.68% | -7.72% |
| 5-year return | +52.84% | -48.29% |
| P/E ratio (TTM) | 3.54 | — |
| Forward P/E | 20.74 | — |
| EPS (TTM) | $2.05 | $-3.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $311.71M | $67.48M |
| Revenue growth (YoY) | +617.03% | +25.24% |
| Net income (latest FY) | $163.06M | $-278.67M |
| Gross margin | 88.46% | — |
| Operating margin | 48.17% | -449.94% |
| Net margin | 52.31% | -412.95% |
| 52-week high | $13.02 | $13.90 |
| 52-week low | $6.13 | $7.36 |
| Distance from 52-week high | -44.24% | -34.68% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +111.16% | +250.77% |
| Average volume | 1.11M | 1.82M |
| Shares outstanding | 77.94M | 88.96M |
| Employees | 191 | 260 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KURA has outperformed CRMD by 21.0 percentage points over the past year.
- CorMedix is more profitable, keeping 52.3 cents of every revenue dollar as net income versus -412.9 cents for Kura Oncology.
- CorMedix grew revenue faster in its latest fiscal year (+617.03% vs +25.24%).
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Healthcare · Biotechnology · 191 employees
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Healthcare · Biotechnology · 260 employees
CRMD vs KURA FAQ
Which is bigger, CorMedix or Kura Oncology?
Kura Oncology (KURA) is larger, with a market capitalization of $807.76M compared with $565.88M for CorMedix (CRMD).
Which stock has performed better over the past year, CRMD or KURA?
KURA returned -7.72% over the past 12 months, compared with -28.68% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Are CorMedix and Kura Oncology in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.